There is an increasing need for sensitive and specific methods for toxicological screening. Development of a dual-column gas chromatography system for the screening of drugs and metabolities in the plasma of poisoned patients is described. The system has been evaluated using plasma from a wel1-documented series of patients presenting with overdose, and results obtained have been compared with results of specific assays for the groups of drugs encountered. The method has been found to be of value in the treatment of poisoned patients despite its apparent insensitivity to certain more polar drug metabolities such as nortriptyline and desmethyldiazepam.
Deliberate self-poisoning is responsible for a substantial proportion of emergency admissions of adults to hospital. In the United Kingdom it accounts for about 10% of the total medical admissions and is the cause of coma in 25-50% of unconscious patients. At one centre it is estimated that about 50% of poisoned patients ingest more than one drug in overdosage and, in addition, about 70% of the males and 40% of the females also take alcohol at the same time. I Emergency treatment of acutely poisoned patients is frequently based on clinical symptoms and consists of the provision of supportive therapy, irrespective of the substance ingested. In a few cases specific treatment is available (for example, N-acetyl cysteine or methionine for paracetamol), or procedures exist for increasing the rate of elimination of toxins such as forced alkaline diuresis (for example, in phenobarbitone or salicylate poisoning), haemodialysis, and haemoperfusion using activated charcoal or, more recently, uncharged resins such as XAD-4. 2 In such cases, rapid identification of toxic substances by a screening procedure may reduce morbidity and mortality.
Drug screening should not be used merely to confirm the diagnosis suspected from the clinical symptoms, history or information obtained from the patient or relatives, general practitioner, etc. regarding the availability of drugs.? Although about 75% of patients who 92 take drug overdoses ingest medicines which they have been prescribed or which have been prescribed for close relatives," it is important to bear in mind that information obtained from patients regarding the nature and quantity of drugs ingested correlates poorly with the identity and concentration of drugs found in plasma or urine.
Drug screening is of paramount importance in the case of deeply unconscious patients in whom there is doubt about the nature and variety of drugs taken, and in seriously il1 patients not responding to conventional medical therapy where poisoning is thought to be a possible cause.
Drug screening is also of considerable value in the case of non-accidental poisoning or child abuse, the name given to the deliberate administration of a potentially toxic agent to a child, usually by one of the parents. This form of poisoning is becoming increasinrly common particularly in the London area .:': 6 The diagnosis of poisoning in childhood may present additional difficulties, not usually encountered with adults. There can be a wider range of differential diagnoses for an acute episode and certain compounds, such as salicylate, can exhibit more profound toxic effects in very young children. In addition, the patient may be unable to give useful information, and information obtained from the parents may be vague or misleading, especially if they have been responsible for unauthorised drug administration.
In cases of suspected brain death, a drug screen is often considered mandatory before removing life-supporting systems. There is an increasing demand for this very important form of drug screening for which a highly sensitive method of "detection is required.
Analytical techniques currently employed for screening drugs include simple colorimetric tests," spectrophotometry, thin-layer chromatography (TLC), gas chromatography (GC), high-performance liquid chromatography (HPLC) , EMIT·, radioimmunoassay and GC or HPLC coupled with mass spectrometry (MS).
Thin-layer chromatography" is a valuable technique for the detection of mixtures of drugs but it is labour-intensive, requires practice in interpretation and usually provides qualitative or, at best, semi-quantitative information. In spite of these disadvantages it is widely used and an attempt has been made to standardise systems for the identification of drugs and poisons."
High-performance liquid chromatography has been extensively used for the analysis of drugs and metabolites but it has been used only to a limited extent for drug screening.l'' A comparison of the advantages and disadvantages of TLC, GC and HPLC for drug screening has been carried out by Stewart. II Immunoassay screening kits are now available for an increasing number of drugs or groups of drugs, for example EMIT® kits can be used for the detection of benzodiazepines, barbiturates and tricylic antidepressants in serum and for a range of drugs of abuse in urine;" The EMIT® assays are rapid, easy to use and accurate but the kits are expensive and a separate kit is required for each drug or group of drugs. The specificity of the EMIT® drug abuse urine assays has been investigated'f and, although in general specificity is good, there are some serious cases of interference, for example codeine reacts in the same way as morphine in the opiate assay.
Gas chromatographyl" 15 can be used for the separation and identification of mixtures of drugs, metabolites and poisons but resolution of complex mixtures on a single GC column may not be possible. A second column may yield more information, allowing confirmation 'EMIT is a trade mark of the Syva Company.
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of overlapping peaks, ie but only if its retention characteristics are sufficiently different from the first. If the drugs elute in the same order on both columns, then the information given by the dual column system may be little more than that given by a single column. In practice, therefore, the two columns chosen must have widely different characteristics, usually differing in polarity. We describe the development of a dualcolumn GC system with temperature programming which provides a screening system for a wide range of drugs, metabolites and toxic substances. The system was tested both with pure drugs and with a limited series of plasma samples from 43 patients whose case histories were well documented. Most of these were poisoned with tricylic antidepressants or benzodiazepines, two of the commonest classes of drugs taken nowadays in overdose. Sensitive and specific confirmatory assays for these and other groups of drugs were performed on the same samples and the results compared. The system can also be used for basic drugs in urine, but the presence of metabolites may complicate the analysis.
Materials and methods

DEVELOPMENT OF THE DUAL-COLUMN GC
SYSTEM
In order to test different packing materials a series of 60 pure compounds was prepared (59 common drugs plus cholesterol, a common interfering substance in plasma extracts). Free acids, bases and neutral substances were dissolved in ethanol at a concentration of 1 gil. Salts were dissolved in water at the same concentration, made acidic or alkaline as appropriate, and extracted into an equal volume of chloroform.
Stationary phases were coated by solvent evaporation on to chromosorb W, 100-120 mesh, which had been acid-washed, basewashed and silanised in the laboratory.l" This was found to give more satisfactory results than commercially-treated material. The following packings were prepared: OY-17, Poly-A 103, cyclohexanedimethanol succinate (CDMS), carbowax 20M (terminated with terephthalic acid) and OY-275. These were packed into silanised glass columns and run isothermally in a Pye 104 gas chromatograph under the conditions shown in Table 1 . Nitrogen carrier gas and flame-ionisation detection were used. Solutions containing 1-5 !Jog of pure drug were injected into the GC; tetraphenylethylene (Aldrich Chemical Co., Gillingham, Dorset, UK) was used as a standard to provide relative retention data.
Single columns were assessed by comparing the number of the standard drugs eluted, and the distribution of their relative retention times transformed logarithmically ( Table 2 ). The larger the standard deviation of this distribution the more effective was the packing at resolving mixtures of drugs. Using these criteria, OY-17 was selected as the primary column. Other advantages of OY-I7 are its high maximum temperature, long-term stability and column efficiency.
Column pairs were assessed by examining the correlation between the relative retention times on each column, transformed logarithmically. The lower the correlation coefficient, the more information is given by the column combination. These data are plotted in Figures 1 and 2 and summarised in Table 2 . Useful combinations with OY-I7 are given by carbowax 20M and OY-275. Carbowax 20M has a higher column efficiency than OY-275 and detects more of the test drugs, but it has a low maximum temperature and poor long-term stability (retention times decrease markedly with the age of the column). OY-275 has a temperature maximum which allows chroma- 
Reagents
The standard solutions used are 2-amino-5chloro-benzophenone (ACB), 200 mg/l in ethanol and ACB, 40 mg/l in ethanol containing triethylamine (0·1 % vol/vol). The solvent for injection is ethanol containing triethylamine (0,1 % vol/vol),
Apparatus
The equipment consists of a Perkin-Elmer Sigma 3B GC system with a flame-ionisation detector (channel A) and nitrogen-phosphorus detector (channel B Preliminary extraction from plasma Drugs in plasma are assayed after extraction into ether; the same portion of plasma is used for extraction of acidic, basic and neutral drugs so that only 0·5 ml of plasma is required.
tography of the less volatile drugs, although peak shape has been found to deteriorate somewhat during the life of a column. For comparison the correlation of Poly-A103 and CDMS is shown; this system yields little more information than either packing material used alone. Temperature programming is the best approach for screening work involving drugs of widely differing volatility. Using the program described below, a total of 111 pure drugs and metabolites were tested on an QV-17/QV-275 combination. An atlas of relative retention times was constructed, using as retention standard 2-amino-5-chloro-benzophenone (ACB) (Sigma Chemical Co., Poole, Dorset, UK). This standard elutes in approximately 5 min on both columns. Since nearly all drugs encountered contain nitrogen, a nitrogen-phosphorus detector was used in the QV-17 channel, which reduced interference by endogenous compounds and increased the sensitivity of the method. Triethylamine base was incorporated in the solvent for injection into this channel to provide a 'solvent front' for measurement of retention times.
is added to the dried residues and the contents are mixed for 20 seconds on a vortex mixer.
A sample (5 ul) is injected into column Band the temperature program activated. When the oven temperature display reads 203°C a second sample (5 !J.1) is injected into column A. The chromatograms are recorded for 25 minutes, and the retention times of all significant peaks are determined.
The method described is also applicable to urine as far as the basic extraction but cannot be applied to acidic drugs in urine because acid extracts result in column contamination.
Calibration and identification
A sample of 40 mg/l ACB (5 ul) is injected into column B and the temperature program started. When the oven temperature reaches 203°C a sample of 200 mg/l ACB (5 ul) is injected into column A. The chromatograms are recorded until the peaks elute (approximately 5 minutes).
The retention times of sample peaks relative to ACB are then calculated and identification attempted using a reference table of relative retention times on column B. The identity may be confirmed by the presence of a peak on column A with the relative retention time appropriate for the suspected drug.
The relative retention time can be checked using a solution of the pure drug in ethanol contining 0·1% vol/vol triethylamine (about 1 mg drug/ml). A better method of confirmation is by co-chromatography by simultaneously injecting an appropriate volume of extract containing the unknown material together with pure drug solution (1 ul), This chromatographic method employs external rather than internal standardisation to avoid the masking of unknown peaks by ACB and to overcome the difficulty introduced by the two concentrations of ACB solution required. The method depends on accurate measurement of the 5 !J.l injection volume, free from air bubbles, and a good injection technique. This is controlled to a certain extent by monitoring the size of the triethylamine peak eluting soon after injection.
In practice unidentified peaks are encountered from time to time using the screening procedure and, when this occurs, the sample extracts are subsequently investigated using a GC-MS system with an QY-17 column. In this way it is possible to extend progressively the reference table of relative retention times.
Quantitation
The method is not quantitative but an approximate measure of the severity of poisoning can be obtained by determining the ratio of the peak height of the suspected drug peak to that of the ACB peak. This can then be compared with the corresponding peak height ratio obtained for a solution of a known concentration of pure drug in horse serum and ACB.
CONFIRMATORY METHODS
Tricylic antidepressants (HPLC)
Tricylic antidepressants were measured by the HPLC method of Watson and Stewart;" modified by the use of perphenazine as internal standard and by increasing the concentration of propan-2-ol in the HPLC solvent to 10% by volume.
Benzodiazepines (GC)
Benzodiazepines were measured using a Pye 104 GC with temperature programming and electron capture detection. To 0·1 ml of serum were added 0·05 ml of 2 mg/l ACB as internal standard and 0·05 ml of ammonia solution (S.G. 0,880). The mixture was extracted into 5 ml ether; 0·2 ml toluene was added to the ether which was then reduced in volume under nitrogen at 40°C until 30-40 ul remained. Two microlitres of this was injected into the GC.
GC conditions were as follows: column 3% QY-17 on Chromosorb W (3 feet); oven temperature, increased from 250°C to 300°C at 12°C per min, then held at 300°C for 5 min; detector temperature, 350°C; pulse space, 50 usee; attenuation, 5 x leY; carrier gas flow, 60 ml/min; purge gas flow, 40 mllmin.
Using this technique all the commonly encountered benzodiazepines could be separated and identified. All except temazepam and chlordiazepoxide gave linear responses and could be quantitated; temazepam could be measured approximately; chlordiazepoxide broke down non-reproducibly and could be identified but not quantitated.
Barbiturates (GC)
Barbiturates were extracted from acidified serum or plasma into ether and measured by GC without derivatisation. Quantitation was achieved by measuring the proportionate increase in peak height of one of a standard mix of barbiturates added to the plasma.
GC conditions were as follows: instrument, Perkin Elmer Sigma 3 with flame ionisation detector; column, 10% Apiezon Lon Chromosorb W (1 m); oven temperature, increased from 180°C to 250°C at 10°C per minute; injector and detector temperature, 280°C; carrier gas flow, 60 mVmin.
Phenytoin (GC)
Phenytoin was extracted from acidified serum or plasma into ether and measured by GC of the methylated derivative. Tolyphenylhydanto in was used as an internal standard.
GC conditions were as follows: instrument, Perkin Elmer Sigma 3 with nitrogen detector; column, 2% CDMS on Chromosorb W (1 m); oven temperature, 220°C; injector and detector temperatures, 240°C; carrier gas flow, 60 rnl/ min.
Methaqualone (GC)
The concentration of methaqualone was measured using the GC method described for barbiturates, modified by holding the final oven temperature at 250°C until the methaqualone peak had eluated. Heptabarbitone was used as internal standard.
Results
The findings are summarised in Table 3 which lists the range of drugs and metabolites detected in plasma by the screening procedure compared with specific assay methods. Where quantitative analyses were performed the concentration or range of concentrations is shown. In six cases identification of the drug or metabolite was not confirmed by an alternative method but the presence of the material was supported by other evidence, e.g. the finding of the parent drug or a metabolite in the plasma, information obtained from relatives, etc.
In 87% of the samples containing amitriptyline the plasma concentration was greater than 430 I-1g/l and the drug was correctly identified; in the remaining four samples in which the screening method failed to detect the drug, it was present in a concentration equal to or less than 430 ug/l. In seven out of eight samples the amitriptyline metabolites lO-hydroxyamitriptyline and lO-hydroxynortriptyline were identified; the concentration of these substances in plasma was not determined. The screening procedure correctly identified imipramine, desmethylimipramine and trimipramine in all samples containing these compounds.
Screening for nortriptyline was much less successful, the procedure failing to identify the substance in 52% of the samples in which nortriptyline was detected by HPLC. The criterion of success does not appear to be simply related to the concentration of nortriptyline in the patient's plasma as is clearly shown in Table  3 . The screening system detected the substance at a concentration as low as 110 I-1g/l while failing to detect its presence at a level of 1360 I-1g/l. This finding is not unexpected since the chromatography of secondary amines on general purpose GC packing material is notoriously difficult; a number of workers found it necessary to introduce a derivatization step in order to improve the chromatography of nortriptyline. 19 The screening system performed well in the detection of diazepam, desalkylflurazepam and chlordiazepoxide failing only when the substances were present at low therapeutic levels. 2o In contrast the procedure failed to detect nitrazepam, temazepam and lorazepam in most samples containing these drugs. However, with the exception of one sample containing nitrazepam, the drug concentrations were within or only slightly above the therapeutic levels quoted by Widdop.20 As in the case of nortriptyline, the screening procedure was much less successful in detecting the desmethyl derivate of diazepam than in detecting the parent drug. The ability to detect desmethyldiazepam was, however, more closely related to concentration than was observed for nortriptyline.
The system performed well in correctly identifying most of the other drugs although only small numbers were involved in this evaluation. In the case of carbamazepine two of the metabolites, carbamazepine-lO,l1-epoxide and 1O,11-dihydroxycarbamazepine, have almost identical relative retention times on the OV-17 column and hence it was not established whether only one or both of these substances were present in samples from patients who had taken a carbamazepine overdose.
The screening procedure has been applied to a number of urine samples from poisoned patients and the substances detected and confirmed include carbamazepine and amitriptyline and their metabolites, thioridazine, chlorpromazine, cimetidine, diphenhydramine and methaqualone.
Two of the most commonly detected peaks in plasma and urine have relative retention times corresponding to caffeine and lignocaine. Lignocaine may be used as a local anaesthetic in intubation and catheterisation and this informa- tion is frequently not indicated by the requesting clinician. Throughout the evaluation there was no conclusive evidence of false-positive results although in two samples peaks with approximately the same retention time as (i) temazepam and (ii) diazepam were detected when there was no evidence to support the presence of. these drugs in the respective samples.
Discussion
The dual-column GC method described has been found to be of considerable value as a drug screening procedure. In addition to its use for the samples involved in the evaluation, the method has been widely used for drug screening mainly for samples from acute drug overdose patients. The method has also been used to identify toxic substances taken in poisoning cases, e.g. 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid. In general the method is employed in conjunction with a UV urine screening procedure for basic drugs and a series of urine spot tests for phenothiazines, imipramine and related compounds, salicylate, paracetamol and metabolites, trichloro-derivatives and chlorate.
The UV urine screening procedure is used as a primary screen for the groups of drugs present. It is particularly useful for the detection of tricylic antidepressants and benzodiazepines including the demethylated compounds for which the sensitivity of the GC method is poor.
The presence of barbiturates in plasma has been established on several occasions using the screening procedure but, if the clinical symptoms and information obtained from other sources suggest the presence of barbiturates, use is made of the previously described GC barbiturate method which provides quantitative as well as qualitative information. Similarly, in cases of suspected salicylate or paracetamol poisoning, screening is usually performed by the Kelle~l method or the Cambridge Life Sciences enzymic assay, 22 respectively.
In addition to its use for self-poisoning cases, the GC method has been employed to screen plasma samples in cases of suspected nonaccidental poisoning in children. A number of such samples have been examined but only one positive result has been obtained. Amylobarbitone was detected in the plasma of an 18month-old boy who was given the drug by one of his parents; the drug was available because it had been prescribed for a grandparent who lived with the family.
Because of the lack of sensitivity, the GC method is of only limited value for the identification of drugs in plasma from patients with suspected brain death. For this important application, a highly sensitive analytical system capable of detecting and measuring a very wide range of drugs and metabolites is essential and a technique employing mass spectrometric detection is the method of choice.
A Sigma 3B GC system is currently used for the screening procedure but any dual-column GC system with a temperature-programming facility would be suitable. The power of the technique is, however, limited by the detector, which must be a relatively non-specific device such as a flame ionisation or nitrogenphosphorus detector since it must respond to as wide a range of drugs as possible. The specificity of GC may be improved by injecting samples into a series of columns containing different stationary phases ranging from highly polar to non-polar materials in order to obtain different elution patterns. A number of relative retention times can be compared with standard values for the different systems. However, the use of multiple columns is time-consuming and costly and may not yield much more information than can be obtained from a well-chosen dualcolumn system.
HPLC has the advantage that it can also be used for non-volatile and thermally unstable compounds and is most useful for the separation of water soluble analytes.!' An HPLC system suitable for screening would, however, require a gradient elution facility and hence would be more expensive than the equivalent GC system. In addition, it is probably less easy to operate and involves the preparation and use of solvents with the associated hazards.
The method of choice for drug screening, especially where multiple drug ingestion is involved, is mass spectrometry. A combined GC-MS 23 , 24 or HPLC-MS 25 system provides a method of analysis with a high resolving power linked to a highly selective detector. These systems are capable of making qualitative and quantitative measurements on a large number of compounds with a high degree of sensitivity and specificity. The GC-MS system is restricted to volatile, thermostable compounds; in the case of non-volatile substances, if is often possible to prepare a volatile derivative.
Although GC-MS has proved to be an excellent method for drug sereening.P' 24 the equipment is highly specialised, expensive, requires a skilled operator and is not available in most hospital laboratories. This present situation may well change with the introduction of 'bench top' systems such as that based on the Hewlett-Packard 5970A mass-selective detector, a relatively inexpensive system controlled by a microprocessor and one that is simple to operate. In this instrument, moreover, the resolving power of the GC component is enhanced by the use of capillary columns.
The use of screening procedures for identifying and quantifying toxic substances can be of considerable value to clinicians managing patients with suspected intoxication. However, it is essential to bear in mind several important points relating to poison screening. The wide variety of compounds ingested in toxic quantities, and the complexity of the mixtures often present in body fluids (some taken in overdose and others given in treatment), presents an extremely difficult drug screening problem. No laboratory screen can be expected to detect the enormous range of substances likely to be encountered and the laboratory staff require as much guidance as possible from clinicians. When requests are made for 'drug screens' the laboratory should be provided with all the relevant information available including grade of coma, approximate time of ingestion of toxin, drugs available to patient, etc. It is also important to indicate clearly any drug used in treating the patient, e.g. lignocaine, which may interfere with analytical procedures.
Despite advances in analytical techniques and instrumentation, with more sensitive and selective detectors, caution is required in the interpretation of results of drug screening procedures. The reliability of drug screening has been assessed in the United States" by sending samples to three commercial laboratories and one academic research laboratory, each using a range of analytical techniques including GC-MS. The findings showed that, in spite of the impression gained that 'drug screen' results weighed heavily in the treatment of overdose patients, emergency qualitative and quantitative analysis of drugs in the serum of such patients frequently yielded misleading results."
